This episode delves into recent regulatory developments across insurance, banking internal models, and clinical evaluation procedures within the EU regulatory landscape.

The European Central Bank has transitioned from an ex ante to an ex post assessment approach for banks' internal credit risk models, allowing more agile implementation of material changes after internal controls confirm regulatory compliance. This change reduces supervisory workloads and focuses on higher-risk cases with targeted on-site investigations.

Additionally, notified body 2797 has issued expert recommendations on implantable cardiac devices, particularly the INGEVITY+ lead device extension, encouraging expanded post-market clinical follow-up to monitor safety and clinical outcomes.

The European Insurance and Occupational Pensions Authority and other bodies conclude multi-year holistic framework implementation assessments, reinforcing regulatory oversight and resilience.

For more information, visit the Carver Agents website.

Articles mentioned:

1. Millions of car finance customers to get payouts this year as FCA goes ahead with compensation scheme
2. Chikungunya Vaccine Vimkunya with French Labelling Available Again in Germany
3. IAIS concludes multi-year cycle of Holistic Framework implementation assessments
4. Urgent Field Safety Notice for SECUDRAPE OP-Mantel by SENGEWALD Klinikprodukte GmbH
5. ECB streamlines how it supervises banks' internal models
6. ECB streamlines how it supervises banks’ internal models
7. ECB streamlines how it supervises banks' internal models
8. EZB vereinfacht Aufsicht über interne Modelle der Banken
9. PRAC maart 2026: waarschuwing voor bekend risico op aseptische meningitis na vaccinatie met Ixchiq
10. Implantable cardiac devices (various) - Notified body 2797 - 15/07/2025 - Expert decision and opinion in the context of the clinical evaluation consultation procedure (CECP)